Search clinical trials for: JNJ-42847922

Total 867 results

Janssen-Cilag International NV

Completed

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants

Healthy

Germany
Janssen Research & Development, LLC

Completed

A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults

Healthy

United States
Janssen Pharmaceutical K.K.

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-42847922 in Healthy Japanese Male Participants

Healthy

Japan
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants

Healthy | Hepatic Impairment

Germany
Janssen Research & Development, LLC

Completed

A Study of JNJ-42847922 (Seltorexant) in Healthy Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study of Seltorexant in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder

Depressive Disorder, Major

Belgium, United Kingdom, Germany, United States, Netherlands
Janssen Research & Development, LLC

Completed

Study to Evaluate Efficacy, Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder Without Psychiatric Comorbidity

Insomnia

Germany, United States, Netherlands
Janssen Research & Development, LLC

Completed

A Study of Seltorexant in Participants With Probable Alzheimer's Disease

Alzheimer Disease

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Effect of Seltorexant Compared to Placebo on Respiration During Sleep in Adult Participants With Obstructive Sleep Apnea

Sleep Apnea, Obstructive

United States
Janssen-Cilag International NV

Completed

Pilot Study to Evaluate the Duration of Effects on Simulated Car Driving and Cognitive Performance After a Single Dose of JNJ-42847922, Zolpidem and Placebo in Healthy Participants

Healthy

Netherlands
Janssen Cilag N.V./S.A.

Completed

Study to Investigate Effects of Repeated Administration of Itraconazole on Pharmacokinetics of JNJ-42847922 in Healthy Male Participants

Healthy

Germany
Janssen Research & Development, LLC

Recruiting

A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult Participants

Renal Impairment

United States
Janssen Research & Development, LLC

Completed

A Study of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Drug Interaction Study in Healthy Participants to Assess the Effect of Rifampin on the Pharmacokinetics of JNJ-42847922

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants

Healthy

United States
Janssen-Cilag International NV

Completed

A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder

Major Depressive Disorder

Belgium, Germany, Netherlands
Janssen Research & Development, LLC

Active, not recruiting

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant

Depressive Disorder, Major

United States, Taiwan, Czechia, Spain, Mexico, South Africa, Colombia, Russian Federation, Brazil, Bulgaria, Sweden
Janssen Research & Development, LLC

Completed

A Study to Investigate the Effect of JNJ-42847922 on Polysomnography Measures in Patients With Major Depressive Disorder With Insomnia Who Are Stably Treated With Antidepressants

Depressive Disorder, Major

Germany, Netherlands
Janssen Research & Development, LLC

Completed

A Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-JNJ-42847922 After a Single Oral Dose of 40 mg in Healthy Subjects

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Depressive Disorder, Major

United States, Bulgaria, Ukraine, Russian Federation, Germany, Finland, Japan, France
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder

Insomnia Disorders

Belgium, United States, Germany, Poland, Japan, France
Janssen Research & Development, LLC

Completed

A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem

Healthy Non-dependent, Recreational Sedative Users | Abuse Potential

United States
National Center for Research Resources (NCRR)
Stanford University

Unknown

Phase II Randomized Study of Intravenous Versus Oral Clomipramine in Patients With Obsessive Compulsive Disorder

Obsessive-Compulsive Disorder

United States
Janssen Research & Development, LLC

Completed

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Depressive Disorder, Major

United States
Janssen Research & Development, LLC

Completed

A Study of Oral Seltorexant as an add-on Medication to an Antidepressant on On-road Driving Performance in Participants With Major Depressive Disorder

Depressive Disorder, Major

Belgium, Germany
Centro Medico del Noroeste
Alfasigma S.p.A.

Recruiting

Endothelial Protection in Post COVID-19 Patients With Sulodexide

Thrombosis | Endothelial Dysfunction | Post COVID-19

Hungary, Mexico
Seoul National University Hospital
Boryung Pharmaceutical Co., Ltd

Active, not recruiting

High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy (SELENIUM)

Ovarian Cancer | Fallopian Tube Cancer | Recurrent Ovarian Carcinoma | Chemotherapy-induced Peripheral Neuropathy | Primary Peritoneal Carcinoma

Korea, Republic of
Verrica Pharmaceuticals Inc.
Paidion Research, Inc.; Instat Consulting, Inc.; Database Integrations, Inc.

Completed

Cantharidin Application in Molluscum Patients (CAMP-2)

Molluscum Contagiosum

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants

Healthy

Belgium
Janssen-Cilag International NV

Completed

A Study to Evaluate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Adult Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

Pharmacokinetic Study of JNJ-42756493 in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants

Healthy

Belgium
Janssen Cilag N.V./S.A.

Completed

Study to Assess the Absorption, Metabolism and Excretion of 14C-JNJ-63623872 After a Single Dose in Healthy Male Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer

Lymphoma, Non-Hodgkin

Denmark, Israel, Spain, Australia
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo

Healthy

Belgium
Tangent Data
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive (JNJ-DEP)

Depression

Moldova, Republic of, Romania
Janssen Pharmaceutical K.K.

Completed

A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants

Healthy

Japan
Janssen Research & Development, LLC

Terminated

An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum

Alzheimer Disease

France, Spain, Netherlands, Belgium, Germany, Sweden
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants

Healthy

United States
Janssen Cilag N.V./S.A.

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38877618 in Healthy Male Participants

Healthy Volunteers

United Kingdom
Janssen-Cilag International NV

Completed

A Study to Investigate the Pharmacokinetics of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male Participants

Healthy
Janssen Pharmaceutical K.K.

Completed

Pharmacokinetic Study of JNJ-56021927 When Taken Orally as Tablet Formulation in Healthy Male Japanese Participants

Healthy

Japan
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate Bioavailability, Food Effect, Safety and Tolerability of a Solid Dosage Formulation of JNJ-54861911 in Healthy Older Male Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus

Obesity and Diabetes Mellitus, Type 2

United States
Janssen Research & Development, LLC

Completed

A Study to Assess Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy Participants

Healthy

Netherlands

3

Subscribe